Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385(9974):1206–18.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  PubMed  Google Scholar 

Guha A, Armanious M, Fradley MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019;29(1):29–39.

Article  CAS  PubMed  Google Scholar 

Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci (Lond). 2020;134(18):2503–20.

Article  CAS  PubMed  Google Scholar 

van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128(7):1040–61.

Article  PubMed  PubMed Central  Google Scholar 

O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51.

Article  PubMed  Google Scholar 

Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.

Article  CAS  PubMed  Google Scholar 

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 125 million people. Lancet. 2014;383(9932):1899–911.

Article  PubMed  PubMed Central  Google Scholar 

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.

Article  PubMed  Google Scholar 

Forrester SJ, Dolmatova EV, Griendling KK. An acceleration in hypertension-related mortality for middle-aged and older Americans, 1999–2016: An observational study. PLoS ONE. 2020;15(1):e0225207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5–12.

CAS  PubMed  PubMed Central  Google Scholar 

Fullerton HJ, Stratton K, Mueller S, Leisenring WW, Armstrong GT, Weathers RE, et al. Recurrent stroke in childhood cancer survivors. Neurology. 2015;85(12):1056–64.

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Prostate Cancer Statistics | CDC.Center for Disease Control and Prevention. 2022 [cited 2023. Available from: https://www.cdc.gov/cancer/prostate/statistics/index.htm. Accessed 30 Dec 2022.

Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–92.

Article  PubMed  Google Scholar 

Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katsi V, Magkas N, Georgiopoulos G, Athanasiadi E, Virdis A, Masi S, et al. Arterial hypertension in patients under antineoplastic therapy: a systematic review. J Hypertens. 2019;37(5):884–901.

Article  CAS  PubMed  Google Scholar 

Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: An Emerging Specialty. Adv Chronic Kidney Dis. 2021;28(5):477–89 e1.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

Article  CAS  PubMed  Google Scholar 

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf. 2015;7:129–38.

PubMed  PubMed Central  Google Scholar 

Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295–307.

Article  PubMed  PubMed Central  Google Scholar 

Ortmann O, Weiss JM, Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1–7.

Article  PubMed  Google Scholar 

Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.

Article  CAS  PubMed  Google Scholar 

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.

Article  CAS  PubMed  Google Scholar 

Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39(12):1314–9.

Article  CAS  PubMed  Google Scholar 

Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective analysis of patients with prostate cancer initiating GnRH agonists/antagonists therapy using a german claims database: epidemiological and patient outcomes. Front Oncol. 2018;8:543.

Article  PubMed  PubMed Central  Google Scholar 

Perrone V, DegliEsposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126(1):9–10.

Article  CAS  PubMed  Google Scholar 

Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96.

Article  CAS  PubMed  Google Scholar 

Patel S. Mechanism and predictors of cardiotoxicity after prostate cancer treatment: a parallel cohort and randomized trial comparing radiation alone, radiation plus leuprolide, and radiation plusrelugolix 2022 [Available from: https://clinicaltrials.gov/ct2/show/NCT05320406. Accessed 30 Dec 2022.

GmbH MS.Relugolix versus leuprolide in patients with prostate cancer: a randomized, open-label study to assess major adverse cardiovascular events (REPLACE-CV) 2022 [Available from: https://www.clinicaltrials.gov/ct2/show/NCT05605964. Accessed 30 Dec 2022.

Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis–immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003;178(3):373–80.

Article  CAS  PubMed  Google Scholar 

Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021;22(6):47.

Article  PubMed  PubMed Central  Google Scholar